Biosimilars in the U.S. and Abroad

Paul Calvo, a director at the intellectual property law firm Sterne, Kessler, Goldstein & Fox, gives viewers a brief update on the status of biosimilars, both in the United States and abroad. He discusses the opposite legal landscapes for biosimilars in the United States and Europe, and offers a prognosis regarding future developments in both markets.

Embed Video


Topics:  Biosimilars, Patents, Pharmaceutical

Published In: Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sterne, Kessler, Goldstein & Fox P.L.L.C. | Attorney Advertising